Allergy Therapeutics
Market Cap
UK£113.1m
Last Updated
2020/09/20 03:08 UTC
Data Sources
Company Financials +
Executive Summary
Allergy Therapeutics plc engages in the research and development of allergy treatments. More Details
Rewards
Risk Analysis
Earnings are forecast to decline by an average of 92.4% per year for the next 3 years
Snowflake Analysis
Excellent balance sheet and fair value.
Share Price & News
How has Allergy Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AGY's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
6.0%
AGY
2.2%
GB Pharmaceuticals
0.1%
GB Market
1 Year Return
39.2%
AGY
9.1%
GB Pharmaceuticals
-14.0%
GB Market
Return vs Industry: AGY exceeded the UK Pharmaceuticals industry which returned 9.1% over the past year.
Return vs Market: AGY exceeded the UK Market which returned -14% over the past year.
Shareholder returns
| AGY | Industry | Market | |
|---|---|---|---|
| 7 Day | 6.0% | 2.2% | 0.1% |
| 30 Day | 25.7% | 1.9% | 0.2% |
| 90 Day | 49.5% | -0.1% | -1.8% |
| 1 Year | 39.2%39.2% | 13.0%9.1% | -10.6%-14.0% |
| 3 Year | -45.8%-45.8% | 54.8%37.4% | -4.5%-16.0% |
| 5 Year | -32.1%-32.1% | 88.9%52.7% | 22.5%-4.8% |
Price Volatility Vs. Market
How volatile is Allergy Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall St
Is Allergy Therapeutics plc (LON:AGY) Popular Amongst Institutions?2 months ago | Simply Wall St
Is Allergy Therapeutics plc's (LON:AGY) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?3 months ago | Simply Wall St
Here's What We Think About Allergy Therapeutics plc's (LON:AGY) CEO PayValuation
Is Allergy Therapeutics undervalued compared to its fair value and its price relative to the market?
13.41x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AGY's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AGY's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AGY is good value based on its PE Ratio (13.4x) compared to the GB Pharmaceuticals industry average (15.3x).
PE vs Market: AGY is good value based on its PE Ratio (13.4x) compared to the UK market (17.7x).
Price to Earnings Growth Ratio
PEG Ratio: AGY's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: AGY is good value based on its PB Ratio (2.2x) compared to the GB Pharmaceuticals industry average (4x).
Next Steps
Future Growth
How is Allergy Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
-92.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AGY's earnings are forecast to decline over the next 3 years (-92.4% per year).
Earnings vs Market: AGY's earnings are forecast to decline over the next 3 years (-92.4% per year).
High Growth Earnings: AGY's earnings are forecast to decline over the next 3 years.
Revenue vs Market: AGY's revenue (6% per year) is forecast to grow slower than the UK market (6.3% per year).
High Growth Revenue: AGY's revenue (6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AGY is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Allergy Therapeutics performed over the past 5 years?
25.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AGY has a large one-off gain of £9.2M impacting its December 31 2019 financial results.
Growing Profit Margin: AGY became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: AGY has become profitable over the past 5 years, growing earnings by 25.3% per year.
Accelerating Growth: AGY has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: AGY has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.8%).
Return on Equity
High ROE: AGY's Return on Equity (16.4%) is considered low.
Next Steps
Financial Health
How is Allergy Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: AGY's short term assets (£57.5M) exceed its short term liabilities (£15.0M).
Long Term Liabilities: AGY's short term assets (£57.5M) exceed its long term liabilities (£21.7M).
Debt to Equity History and Analysis
Debt Level: AGY's debt to equity ratio (3.9%) is considered satisfactory.
Reducing Debt: AGY's debt to equity ratio has increased from 0.3% to 3.9% over the past 5 years.
Debt Coverage: AGY's debt is well covered by operating cash flow (666.3%).
Interest Coverage: AGY's interest payments on its debt are well covered by EBIT (3.9x coverage).
Balance Sheet
Next Steps
Dividend
What is Allergy Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AGY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AGY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AGY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AGY's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AGY's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.8yrs
Average management tenure
CEO
Manuel Llobet (56 yo)
11.17yrs
Tenure
UK£557,159
Compensation
Mr. Manuel Llobet has been the Chief Executive Officer of Allergy Therapeutics plc since July, 2009. Mr. Llobet joined Allergy in September 2009 following the successful refinancing by Azure Ventures Limit ...
CEO Compensation Analysis
Compensation vs Market: Manuel's total compensation ($USD721.80K) is above average for companies of similar size in the UK market ($USD349.92K).
Compensation vs Earnings: Manuel's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 11.17yrs | UK£557.16k | 0.52% £ 590.2k | |
| CFO & Director | 4.25yrs | UK£282.95k | 0.047% £ 53.2k | |
| Group Operations Director | 4.75yrs | no data | no data | |
| Chief Scientific Officer | 4.75yrs | no data | no data | |
| Business Development Director | 10.92yrs | no data | no data | |
| Head of Human Resources | no data | no data | no data | |
| Head of Clinical Science | 3yrs | no data | no data | |
| Head of Communication & Market Development | no data | no data | no data | |
| Group Financial Controller | no data | no data | no data | |
| Company Secretary | 3.83yrs | no data | no data |
4.8yrs
Average Tenure
Experienced Management: AGY's management team is considered experienced (4.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 11.17yrs | UK£557.16k | 0.52% £ 590.2k | |
| CFO & Director | 4.25yrs | UK£282.95k | 0.047% £ 53.2k | |
| Independent Non-Executive Director | 3.25yrs | UK£40.00k | 0.0078% £ 8.9k | |
| Independent Chairman | 9.92yrs | UK£94.00k | 0.027% £ 30.2k | |
| Independent Non-Executive Director | 1.25yrs | no data | no data | |
| Senior Independent Director | no data | UK£49.00k | 0.12% £ 137.8k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 1.83yrs | UK£25.11k | no data |
3.8yrs
Average Tenure
58yo
Average Age
Experienced Board: AGY's board of directors are considered experienced (3.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Allergy Therapeutics plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Allergy Therapeutics plc
- Ticker: AGY
- Exchange: AIM
- Founded: 2004
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£113.118m
- Shares outstanding: 637.29m
- Website: https://www.allergytherapeutics.com
Number of Employees
Location
- Allergy Therapeutics plc
- Dominion Way
- Worthing
- West Sussex
- BN14 8SA
- United Kingdom
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AGYT.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Oct 2004 |
| AGY | AIM (London Stock Exchange AIM Market) | Yes | Ordinary Shares | GB | GBP | Oct 2004 |
Biography
Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of po ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/09/20 03:08 |
| End of Day Share Price | 2020/09/18 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.